UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-01, Vol.34 (1), p.210-223

2020

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

Leukemia, 2021-01, Vol.35 (1), p.177-188

2021

Link zum Volltext

Verfügbarkeit prüfen

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Leukemia, 2019-09, Vol.33 (9), p.2208-2226

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Leukemia, 2022-01, Vol.36 (1), p.138-154

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-07, Vol.34 (7), p.1971-1971

2020

Link zum Volltext

Verfügbarkeit prüfen

Dysfunctional T regulatory cells in multiple myeloma

Blood, 2006-01, Vol.107 (1), p.301-304

2006

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (24), p.11712-11720

2005

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy Strategies in Multiple Myeloma

Hematology/oncology clinics of North America, 2014-10, Vol.28 (5), p.927-943

2014

Link zum Volltext

Verfügbarkeit prüfen

Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

Journal of Immunology, 2007-06, Vol.178 (12), p.7730-7737

2007

Link zum Volltext

Verfügbarkeit prüfen

O13-5 Rejuvenated BCMA-specific CD8αβ+ memory T cells to treat multiple myeloma using induced pluripotent stem cell technology

Annals of oncology, 2023-11, Vol.34, p.S1389-S1390

2023

Link zum Volltext

Verfügbarkeit prüfen

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Leukemia, 2018-09, Vol.32 (9), p.1932-1947

2018

Link zum Volltext

Verfügbarkeit prüfen

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.3195-3195

2018

Link zum Volltext

Verfügbarkeit prüfen

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8+ cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Blood, 2018-11, Vol.132 (Supplement 1), p.3196-3196

2018

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Leukemia, 2024-05, Vol.38 (5), p.1189-1190

2024

Link zum Volltext

Verfügbarkeit prüfen

Development of B-cell maturation antigen (BCMA)-specific CD8 + cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2542-2542

2022

Link zum Volltext

Verfügbarkeit prüfen

Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.75-75

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.(Correction notice)

Leukemia, 2020-07, Vol.34 (7), p.1971

2020

Link zum Volltext

Verfügbarkeit prüfen

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.3138-3138

2019

Link zum Volltext

Verfügbarkeit prüfen

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-01, Vol.34 (1), p.210

2020

Link zum Volltext

Verfügbarkeit prüfen

Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14302-e14302

2019

Link zum Volltext

Verfügbarkeit prüfen

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8.sup.+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Leukemia, 2019-09, Vol.33 (9), p.2208

2019

Link zum Volltext

Verfügbarkeit prüfen

Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies

Clinical cancer research, 2005-02, Vol.11 (4), p.1629-1638

2005

Link zum Volltext

Verfügbarkeit prüfen

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma

Blood, 2024-03, Vol.143 (10), p.895

2024

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

JAMA oncology, 2018-12, Vol.4 (12), p.e183267

2018

Link zum Volltext

Verfügbarkeit prüfen

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells

The Journal of immunology (1950), 2013-02, Vol.190 (3), p.1360-1371

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(67)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Humans
(23)
Life Sciences & Biomedicine
(22)
Oncology
(15)
Multiple Myeloma
(14)
Hematology
(13)
Cell Line, Tumor
(12)
Immunotherapy
(12)
Antigens
(11)
Multiple Myeloma - Immunology
(11)
Lymphocytes
(10)
T-Lymphocytes, Cytotoxic - Immunology
(10)
Cytotoxicity
(9)
Lymphocytes T
(9)
Multiple Myeloma - Therapy
(9)
Peptides
(9)
Biological And Medical Sciences
(8)
Cell Proliferation
(8)
Medical Sciences
(8)
Cd8 Antigen
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Dysfunctional T regulatory cells in multiple myeloma

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Immunotherapy Strategies in Multiple Myeloma

Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

O13-5 Rejuvenated BCMA-specific CD8αβ+ memory T cells to treat multiple myeloma using induced pluripotent stem cell technology

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8+ cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Development of B-cell maturation antigen (BCMA)-specific CD8 + cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.(Correction notice)

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1)

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8.sup.+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells

Suchergebnisse filtern